For a cohort of 219 patients with stage III NSCLC who received definitive concurrent chemoradiotherapy, 25 patients (11.4%) underwent PBSPT and 194 patients (88...
In the early-stage NSCLC setting, all of the studies had a small sample size and were single-arm without direct comparison. Proton therapy was promising for...
This study reported results of PBT for 54 patients of inoperable stage I to III NSCLC with poor lung functions (defined as FEV1 ≤1.0 L, or FEV1≤50% predicted or...
This study presented outcomes of a prospective multicenter trial with an early closure. Twenty-eight patients with stage II or III unresectable NSCLC were...
Data of 140 dosimetry studies was analyzed. In the 105 non-SABR studies, the average MHD was similar between IMRT and 3DCRT (10.9 Gy versus 10.6 Gy) and lower...
With data of 41 patients with stage III NSCLC who received PBT of 74 GyE with concurrent chemotherapy, this study reported that bone V5-20 and lung V5-50 were...
This review provided systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable locally advanced NSCLC. Based on 19 studies...
Based on the ‘Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline’, this summary document makes recommendations directly related to RT for the...
This study retrospectively review 69 patients with esophageal cancer treated with XRT (n=15) and PBT (n= 54) and concurrent chemotherapy. The study found that...